AVAVA has pioneered two devices
Both employ the core enabling Focal Point Technology™ and Intelliview innovation to unlock multiple clinical indications
The FDA adopted Focal Point Technology™ as a new class of intradermal lasers and granted AVAVA a first‑in‑class regulatory clearance for high energy up to 150mj energy dose.
Both devices are FDA-cleared and deliver a, non-invasive, breakthrough procedure that promotes skin health, treats skin aging, and can safely treat pigmentary disorders. The design inherent in Focal Point Technology™ spares damage to the epidermis by reducing fluence and allows depth control making it safe for use on all skin colors.
The FDA adopted Focal Point Technology™ as a new class of intradermal lasers and granted AVAVA a first‑in‑class regulatory clearance for high energy up to 150mj energy dose.
Both devices are FDA-cleared and deliver a, non-invasive, breakthrough procedure that promotes skin health, treats skin aging, and can safely treat pigmentary disorders. The design inherent in Focal Point Technology™ spares damage to the epidermis by reducing fluence and allows depth control making it safe for use on all skin colors.
Launching 2023for skin health
treatment of skin aging and scars 
|
Launching 2024for pigmentary disorders
Melasma / Hyperpigmentation 
|